Tag: pharmaceutical

ROCKVILLE, Md. and SUZHOU, China, July 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced the appointments of Veet Misra, Ph.D., as the Company’s Chief Financial Officer, and Mr. Eric Huang, as Senior Vice President of Global Corporate Development and Finance. Both Dr. Misra and Mr. Huang will report directly to Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer.

Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) -- Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation. 

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against West Pharmaceutical Services, Inc. (“West” or “the Company”) (NYSE: WST) and certain of its officers.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options

PRESS RELEASE

Munich, Germany, July 04, 2025 – The Strüngmann Award selection committee today announced that Dragan Grabulovski, Ph.D., Philipp Spycher, Ph.D., and Isabella Attinger-Toller, Ph.D., the founders of Araris Biotech, have been honored as this year’s winners. The award aims to support outstanding entrepreneurial and scientific achievements, as well as ground-breaking ideas in the life sciences industry. Araris Biotech’s founding team distinguished itself not only by developing of a novel technology in the antibody-drug conjugates (ADCs) field, but also by successfully validating this innovation through partnerships and a preclinical exit. This new drug class has the potential to significantly advance the development of targeted cancer therapies, thereby delivering added value for people living with cancer worldwide.